1 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

2 Genomic characterization of the complete terpene synthase gene family from Cannabis sativa.

3 Treating patients with opioid use disorder.

4 Proceedings of the 23 Annual Conference of the European Society for Domestic Animal Reproduction (ESDAR), St Petersburg, Russia, 19-22 September 2019.

5 Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006

6 Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus

7 The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007

8 Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites

9 Family physicians' knowledge and screening of chronic hepatitis and liver cancer

10 Telaprevir for previously untreated chronic hepatitis C virus infection

11 Boceprevir for untreated chronic HCV genotype 1 infection

12 The Institute of Medicine report on viral hepatitis: a call to action

13 Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States

14 The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

15 The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings

16 The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

17 Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma

18 seropositivity of hepatitis b and c among syrian multitransfused patients with hemoglobinopathy

19 The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C

20 Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens

21 Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals

22 [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]

23 Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

24 Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

25 Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

26 Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

27 Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

28 A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C

29 An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

30 Acute hepatitis B in patients with or without underlying chronic HCV infection

31 Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

32 Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

33 Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

34 Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?

35 Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis

36 Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C

37 Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents

38 Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

39 Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

40 Sofosbuvir for previously untreated chronic hepatitis C infection

41 Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

42 A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin

43 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

44 Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

45 How expensive may drugs be? The example of hepatitis C drugs

46 Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

47 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

48 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

49 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

50 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

51 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

52 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

53 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

54 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

55 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

56 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

57 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

58 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

59 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

60 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

61 Conceptual framework for outcomes research studies of hepatitis C: an analytical review

62 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

63 Approaches to hepatitis C treatment and cure using NS5A inhibitors

64 Current treatment of choice for chronic hepatitis C infection

65 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

66 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

67 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

68 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

69 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

70 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

71 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

72 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

73 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

74 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

75 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

76 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

77 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

78 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

79 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

80 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

81 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

82 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

83 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

84 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

85 Conceptual framework for outcomes research studies of hepatitis C: an analytical review

86 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

87 Approaches to hepatitis C treatment and cure using NS5A inhibitors

88 Current treatment of choice for chronic hepatitis C infection

89 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

90 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

91 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

92 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

93 Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective

94 Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital

95 Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia.

96 The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.

97 Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.

98 Real-world effectiveness and safety of Ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.

99 Infant follow-up postdelivery from a hepatitis C viral load positive mother

100 The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens

101 Challenging hepatitis C-infected liver transplant patients

Keyword Connections

Journals

Research Groups

Bibliographies